Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatment for the Prevention of Respiratory Viral Infections
– Phase 2b study will investigate the efficacy of REVTx-99 on viral load and patient-reported…
Four Inc. Secures Spot on Washington Technology’s Top 100 Government Contractors List for 11th Consecutive Year
Tat Hong Equipment Service Co., Ltd. Announces 2025/26 Annual Results